Myriad Completes Spin Off of Pharma Business | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market Wednesday that it has completed the spin off of Myriad Pharmaceuticals.

The spin off happened on schedule, with Myriad Genetics' shareholders of record as of June 17, receiving a pro-rata dividend of one quarter of a share of Myriad Pharmaceuticals for each share of Myriad Genetics. Fractional shares were paid in cash, the firm said.

As of yesterday, Myriad Genetics has no ownership of Myriad Pharmaceuticals, and the two firms operate completely independently of each other.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."